Who Owns Farxiga?
Farxiga is owned by AstraZeneca plc, the British-Swedish pharmaceutical company listed on the London and Nasdaq exchanges under ticker AZN. The dapagliflozin tablet won US FDA approval for type 2 diabetes in 2014 and has since added heart failure and chronic kidney disease indications, generating approximately $6.8 billion in global revenue in fiscal 2025 and ranking among AstraZeneca's best-selling products.
Parent Company
Founded
2014
Status
Publicly Traded
Headquarters
Farxiga Timeline
Who Owns Farxiga?
- Parent Company: AstraZeneca PLC
- Ownership Type: Brand division
- Company Type: Publicly Traded
- Stock Ticker: London Stock Exchange (also Nasdaq): AZN
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Farxiga | AstraZeneca PLC | Brand division |
Where to Buy
Disclosure: We may earn commission from purchases
Farxiga on AmazonAdvertisement
History of Farxiga
- Founded: 2014
- Founders: AstraZeneca
AstraZeneca developed dapagliflozin through the 2000s as part of the emerging SGLT2 inhibitor class, which lowers blood sugar by promoting glucose excretion in urine. The FDA approved Farxiga for type 2 diabetes in January 2014, entering a market dominated by metformin and injectable therapies.
The pivotal DECLARE-TIMI 58 trial demonstrated cardiovascular benefits, and in 2020 the FDA expanded Farxiga's label to include heart failure with reduced ejection fraction, the first SGLT2 inhibitor approved for that use. Chronic kidney disease approval followed in 2021.
These indication expansions transformed Farxiga from a diabetes drug into a multi-organ platform product. Sales climbed from under $2 billion at diabetes-only status to approximately $6.8 billion in fiscal 2025, driven by heart failure and CKD uptake.
Patent protection in the United States extends into the mid-2020s with generic challenges expected from 2026 onward, creating a revenue cliff AstraZeneca is managing through combination products and pipeline replacement.
Advertisement
About AstraZeneca PLC
Is AstraZeneca a British or Swedish company?
AstraZeneca is a British-Swedish company. It was formed in 1999 by merging Sweden's Astra AB with the UK's Zeneca Group. Legally it is a UK public limited company headquartered in Cambridge, England, though it retains major operations in Sweden.
Is AstraZeneca publicly traded?
Yes. AstraZeneca PLC trades primarily on the London Stock Exchange under ticker AZN, where it is one of the largest FTSE 100 companies, and it maintains a secondary listing on Nasdaq under the same ticker.
When was AstraZeneca founded?
AstraZeneca was formed in 1999 through the Astra-Zeneca merger. Its roots extend to 1913, when Astra was founded in Sweden, and to Zeneca's 1993 spin-off from Imperial Chemical Industries.
Who leads AstraZeneca?
Pascal Soriot has been chief executive officer since 2012. He is credited with rebuilding the company's pipeline, rejecting Pfizer's 2014 takeover bid, and driving its current position as a top-tier oncology and rare disease company.
Advertisement
What is AstraZeneca's market position?
AstraZeneca is a top-10 global pharmaceutical company with $58.7 billion in 2025 revenue. It is a global leader in oncology and operates major franchises in CVRM, respiratory, and rare disease, with 16 blockbuster medicines and approximately 94,000 employees.
What are AstraZeneca's biggest products?
Tagrisso, Farxiga, Imfinzi, Lynparza, Soliris, Ultomiris, and Symbicort are among its largest products. Oncology alone generated $25.6 billion in 2025, and the company counts 16 medicines with annual sales above $1 billion.
- Founded: 1999
- Headquarters: Cambridge, England, United Kingdom
- Company Type: Publicly Traded
- Stock: London Stock Exchange (also Nasdaq): AZN
- Revenue: $58.74 billion total revenue (FY2025)
- Employees: Approximately 94,000
Where Is Farxiga Made / Based?
- Headquarters: Cambridge, United Kingdom (parent AstraZeneca)
- Manufacturing / Operations: United Kingdom, United States, China
Farxiga Categories & Tags
Farxiga Recalls & Controversies
Farxiga has faced no major recalls. Known adverse effects include genital infections, ketoacidosis risk, and dehydration warnings carried on its label, standard for the SGLT2 class. The FDA required updated labeling on ketoacidosis risk after post-market reports.
AstraZeneca has faced litigation over pricing and patent practices common to major pharmaceutical brands, but no drug-specific safety scandal attaches to Farxiga.
Advertisement
Brands Owned by AstraZeneca PLC
Healthcare PharmaceuticalsAstraZeneca
Owned by AstraZeneca PLC
British-Swedish pharmaceutical brand behind Tagrisso and Farxiga, owned by publicly traded AstraZeneca PLC formed by merger in 1999.
pharmaceuticalsprescription-drugsoncology
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsOnglyza
Owned by AstraZeneca PLC
Saxagliptin DPP-4 inhibitor for type 2 diabetes, acquired outright by AstraZeneca in 2014 and later discontinued in the US and Europe as generics entered the market.
diabetestype-2-diabetesdpp-4-inhibitor
Farxiga Ownership: Pros & Cons
Advantages
- +Multi-indication product spanning three major disease areas
- +Approximately $6.8 billion annual revenue with growth trajectory
- +Strong clinical trial data supporting expanded use
- +Global reach across 100-plus markets
- +First-mover advantage in SGLT2 heart failure indication
Considerations
- -Patent cliff begins 2026 with generic competition expected
- -Jardiance leads the class by market share
- -GLP-1 drugs compress the core diabetes market
- -Pricing pressure from payers and government negotiations
- -Single-molecule dependency for all indications
Advertisement
Frequently Asked Questions About Farxiga
Sources & Further Reading
Advertisement
Competitors to Farxiga
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | Germany (Boehringer Ingelheim) | 2014 | Market leader | Global | All Genders | |
| Astrazeneca | United Kingdom (parent AstraZeneca) | 2012 | Niche | Global | All Genders | |
| Boehringer Ingelheim | Germany | 1885 | Market leader | Global | All Genders | |
| Eli Lilly | USA | 1876 | Market leader | Global | All Genders | |
| Sanofi | France | 1973 | Market leader | Global | All Genders | |
| Astrazeneca | United Kingdom | 1999 | Market leader | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Healthcare PharmaceuticalsAstraZeneca
Owned by AstraZeneca PLC
British-Swedish pharmaceutical brand behind Tagrisso and Farxiga, owned by publicly traded AstraZeneca PLC formed by merger in 1999.
pharmaceuticalsprescription-drugsoncology
Competitive Analysis
Market Positioning: Farxiga competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Farxiga
Looking for brands with different ownership structures? These similar brands are not owned by AstraZeneca PLC, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsJardiance
Owned by Boehringer Ingelheim
Empagliflozin SGLT2 inhibitor for type 2 diabetes, heart failure, and kidney disease, co-marketed by Boehringer Ingelheim and Eli Lilly since its 2014 launch.
pharmaceuticalsprescription-drugsdiabetes
Privately Owned
Jardiance is privately owned, unlike Farxiga which is under a publicly traded parent company.
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Privately Owned
Boehringer Ingelheim is privately owned, unlike Farxiga which is under a publicly traded parent company.
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Publicly Traded
Eli Lilly operates independently without a large parent corporation.
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Publicly Traded
Sanofi operates independently without a large parent corporation.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Publicly Traded
Amgen operates independently without a large parent corporation.
AstraZeneca PLC Stock Information
Advertisement
Jobs at AstraZeneca PLC
Latest News About Farxiga
Advertisement
Related Articles About Farxiga
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
Health
Generic vs Brand Name Drugs: Same Company or Different
Teva is the world's largest generic drugmaker (~6% US share). Sandoz was spun off Novartis in 2023. Viatris came from Mylan + Pfizer's Upjohn. Pfizer itself holds hundreds of ANDAs. Explore our database.
Who Brands StaffOct 30, 2026
Generic DrugsBrand NamePharmaceuticals
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization